Patent

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, February 17, 2024

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).
  • IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe.
  • We are working hard to obtain interim results in 2024.
  • With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma.

AgriFORCE Granted Further Patent from the USPTO Related to its FORCEGH+ Facilities

Retrieved on: 
Friday, February 16, 2024

VANCOUVER, British Columbia, Feb. 16, 2024 (GLOBE NEWSWIRE) -- AgriFORCE Growing Systems Ltd. (“the Company”) (NASDAQ: AGRI; AGRIW), an intellectual property (IP) focused AgTech company, today announced that on February 13, 2024, the USPTO granted Patent No.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 16, 2024 (GLOBE NEWSWIRE) -- AgriFORCE Growing Systems Ltd. (“the Company”) (NASDAQ: AGRI; AGRIW), an intellectual property (IP) focused AgTech company, today announced that on February 13, 2024, the USPTO granted Patent No.
  • This continuation patent covers the innovative FORCEGH+ facility design, including its ability to integrate with different automated systems.
  • This patent expands on the Company’s previously announced patent related to its FORCEGH+ facilities.
  • FORCEGH+ facilities are designed as advanced AgTech, high efficiency building envelopes developed through proprietary engineering and materials.

New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

Retrieved on: 
Friday, February 16, 2024

New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:

Key Points: 
  • New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:
    2).
  • Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia.
  • Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success.
  • Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients.

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

Retrieved on: 
Friday, February 16, 2024

HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors"). The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers. In addition, Fusion and the Licensors have signed an agreement to settle the parties' dispute related to an inter partes review ("IPR") of a U.S. patent owned by the Licensors which was instituted in August 2023 by the United States Patent and Trademark Board.

Key Points: 
  • HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors").
  • The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers.
  • Fusion President and Chief Business Officer Mohit Rawat said, "We are pleased to enter into this exclusive license agreement with Heidelberg University and Euratom for their existing patent as we progress FPI-2265, the most advanced actinium-based PSMA targeted radiotherapy currently in development.
  • Under the terms of the license agreement, Fusion will pay the Licensors an aggregate upfront fee of €1.0 million, in addition to certain regulatory milestones upon potential approval and low single-digit royalties on future net sales of applicable products.

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.
  • Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Universal Electronics Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024

Universal Electronics Inc. (UEI), (NASDAQ: UEIC) reported financial results for the three and twelve months ended December 31, 2023.

Key Points: 
  • Universal Electronics Inc. (UEI), (NASDAQ: UEIC) reported financial results for the three and twelve months ended December 31, 2023.
  • We are executing our efficiency initiatives, and our strong gross margins delivered better than expected earnings per share for the fourth quarter of 2023.
  • For a more detailed explanation of Non-GAAP measures, please see the Use of Non-GAAP Financial Metrics discussion, the Reconciliation of Adjusted Non-GAAP Financial Results and the Reconciliation of Adjusted Non-GAAP Financial Outlook and Financial Results, each located elsewhere in this press release.
  • ET / 1:30 p.m. PT, to discuss its fourth quarter and full year 2023 earnings results, review recent activity and answer questions.

Motive Files Lawsuit Against Samsara to Protect Innovation and Fair Competition

Retrieved on: 
Thursday, February 15, 2024

Motive Technologies, Inc. (“Motive”), the only AI-powered Integrated Operations Platform for the physical economy, today filed a lawsuit against Samsara Inc. (“Samsara”) (NYSE: IOT) to protect innovation and fair competition for the benefit and safety of customers.

Key Points: 
  • Motive Technologies, Inc. (“Motive”), the only AI-powered Integrated Operations Platform for the physical economy, today filed a lawsuit against Samsara Inc. (“Samsara”) (NYSE: IOT) to protect innovation and fair competition for the benefit and safety of customers.
  • Despite its efforts, Samsara has failed to develop competitive AI technology and has been losing customers, particularly large Enterprise accounts, to Motive.
  • Rather than develop better products, Samsara has resorted to waging a meritless legal battle and associated marketing campaign against Motive in an underhanded attempt to limit competition and stifle innovation.
  • With today’s filing, Motive seeks to set the record straight and put an end to Samsara’s unlawful and anticompetitive behavior.

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

NaturalShrimp, Inc. Files International Patent Applications

Retrieved on: 
Thursday, February 15, 2024

DALLAS, Feb. 15, 2024 /PRNewswire/ -- NaturalShrimp Incorporated (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), is pleased to announce the successful filing of patents in Japan, Thailand, and Australia. These filings mark a significant step in our commitment to advancing sustainable aquaculture practices and ensuring the future of global seafood production.

Key Points: 
  • These filings mark a significant step in our commitment to advancing sustainable aquaculture practices and ensuring the future of global seafood production.
  • The intellectual property rights represented by the Company's previously issued patents constitute the backbone of NaturalShrimp's business.
  • In this respect, NaturalShrimp has already filed for patent protection in Japan, Thailand, Australia, and the European Patent Convention (EPC), all areas in which the Company is either currently doing business or in which the Company seeks to do business.
  • Patent protection is a very costly process and this extended time period allows the Company to methodically plan and still act with financial responsibility.

UATP Receives Patent Approval for Innovative New Payment Technology

Retrieved on: 
Thursday, February 15, 2024

WASHINGTON, Feb. 15, 2024 /PRNewswire/ -- UATP, the global payment network that enables organizations to simplify payment processes to expand their payment capabilities, has received approval from the US Patent and Trademark Office for patented Enhanced Intermediate Server technology that will improve the speed, efficiency and control of processing transactions for merchants utilizing the UATP One platform. This is the second patent UATP has received for its payment technology since 2021, reflecting its commitment to innovation and exploring new ways to add value for its clients.

Key Points: 
  • The second patent awarded to UATP since 2021 covers technology that speeds and streamlines transactions between acquirers and the UATP One platform.
  • WASHINGTON, Feb. 15, 2024 /PRNewswire/ -- UATP , the global payment network that enables organizations to simplify payment processes to expand their payment capabilities, has received approval from the US Patent and Trademark Office for patented Enhanced Intermediate Server technology that will improve the speed, efficiency and control of processing transactions for merchants utilizing the UATP One platform.
  • This is the second patent UATP has received for its payment technology since 2021, reflecting its commitment to innovation and exploring new ways to add value for its clients.
  • The patent for the parsing engine is the second patent awarded to UATP since 2021, when its Alternative Forms of Payment (AFP) processing solution, Ceptor, was granted patent protection.